Cargando…

Allogeneic HSCT for Symptomatic Female X-linked Chronic Granulomatous Disease Carriers

X-linked chronic granulomatous disease (XL-CGD) is an inherited disorder of superoxide production, causing failure to generate the oxidative burst in phagocytes. It is characterized by invasive bacterial and fungal infections, inflammation, and chronic autoimmune disease. While XL-CGD carriers were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsilifis, Christo, Torppa, Tuulia, Williams, Eleri J., Albert, Michael H., Hauck, Fabian, Soncini, Elena, Kang, Elizabeth, Malech, Harry, Schuetz, Catharina, von Bernuth, Horst, Slatter, Mary A., Gennery, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661721/ https://www.ncbi.nlm.nih.gov/pubmed/37620741 http://dx.doi.org/10.1007/s10875-023-01570-z

Ejemplares similares

Too much of a good thing: a review of primary immune regulatory disorders
por: Tsilifis, Christo, et al.
Publicado: (2023)

Haematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
por: Slatter, M. A., et al.
Publicado: (2023)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

TCRαβ-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined Immunodeficiency
por: Tsilifis, Christo, et al.
Publicado: (2022)

STAT3 Hyper-IgE Syndrome—an Update and Unanswered Questions
por: Tsilifis, Christo, et al.
Publicado: (2021)

Haploidentical CD3(+) TCR αβ/CD19(+)–depleted HSCT for MHC class II deficiency and persistent SARS-CoV-2 pneumonitis
por: Ramanathan, Subramaniam, et al.
Publicado: (2022)

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
por: Morris, Emma C., et al.
Publicado: (2019)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties
por: Greco, Raffaella, et al.
Publicado: (2019)

Recent advances in understanding and treating chronic granulomatous disease
por: Gennery, Andrew
Publicado: (2017)

Neonatal Thoracic Infection with Mixta
por: Tsilifis, Christo, et al.
Publicado: (2021)

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review
por: Sonneveld, Nicole, et al.
Publicado: (2023)

Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom
por: Battersby, Alexandra C., et al.
Publicado: (2019)

Establishing the hematopoietic stem cell transplant (HSCT) in a developing country; the journey of HSCT in Semarang, Indonesia
por: Santosa, Damai, et al.
Publicado: (2020)

A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain
por: Zhang, Shannon, et al.
Publicado: (2019)

Clinical significance of T cell receptor excision circle (TREC) quantitation after allogenic HSCT
por: Mikhael, Neveen Lewis, et al.
Publicado: (2019)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

1689. Active, Invasive Fungal Infection, and Hematopoietic Cell Transplantation (HCT) in Chronic Granulomatous Disease (CGD): Presentation, Procedure, and Outcomes
por: Parta, Mark, et al.
Publicado: (2019)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT
por: Cao, Yigeng, et al.
Publicado: (2022)

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Case Report: Symptomatic Chronic Granulomatous Disease in the Newborn
por: Miladinovic, Milica, et al.
Publicado: (2021)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Quality of Life and Social and Psychological Outcomes in Adulthood Following Allogeneic HSCT in Childhood for Inborn Errors of Immunity
por: Nicholson, Bethany, et al.
Publicado: (2022)

Correction of T-Cell Repertoire and Autoimmune Diabetes in NOD Mice by Non-myeloablative T-Cell Depleted Allogeneic HSCT
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2023)

Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
por: Santos, Paulo Sérgio da Silva, et al.
Publicado: (2023)

Dental consensus on HSCT – Part II: dental Care during HSCT
por: Gobbi, Marcella Ferreira, et al.
Publicado: (2023)

Update on DNA-Double Strand Break Repair Defects in Combined Primary Immunodeficiency
por: Slatter, Mary A., et al.
Publicado: (2020)

Treosulfan-based conditioning for inborn errors of immunity
por: Slatter, Mary A., et al.
Publicado: (2021)

Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art
por: Connelly, James A, et al.
Publicado: (2018)

452 Pseudo-Outbreak of Fulminant Toxoplasmosis in Hematopoietic Stem Cell Transplant [HSCT] Recipients
por: Isa, Flonza, et al.
Publicado: (2014)

Outcome of Hematopoietic Stem Cell Transplantation in patients with Mendelian Susceptibility to Mycobacterial Diseases
por: Radwan, Nesrine, et al.
Publicado: (2021)

Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy
por: Arnold, Danielle E., et al.
Publicado: (2022)

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR(®) study
por: Maziarz, Richard T., et al.
Publicado: (2016)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study
por: Chen, Shan, et al.
Publicado: (2019)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood
por: Day, James W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3d3dm0krdf90qj917kdja2cetk